Clinical Trial Update: Avelumab Treatment in Patients With Neuroendocrine Carcinomas (NEC G3) Progressive After Chemotherapy [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating avelumab in neuroendocrine carcinomas grade 3 after chemotherapy has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cancer
• Neuroendocrine Carcinoma

Drugs mentioned

• Avelumab (avelumab)

Snippet

Sponsor: Johannes Gutenberg University Mainz | Conditions: Cancer | Phase 2 | Status: COMPLETED